Progress on pharmacokinetic study of antibody-drug conjugates.
- Author:
Jianjun GUO
;
Ran GAO
;
Tengfei QUAN
;
Lingyu ZHU
;
Ben SHI
;
Yongyue ZHAO
;
Jing ZHU
;
Mengsha LI
;
Haizhi BU
- Publication Type:Journal Article
- From:
Acta Pharmaceutica Sinica
2015;50(10):1203-9
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugate (ADC) is a new class of therapeutics composed of a monoclonal antibody and small cytotoxin moieties conjugated through a chemical linker. ADC molecules bind to the target antigens expressed on the tumor cell surfaces guided by the monoclonal antibody component. The binding ADC molecules can be internalized and subsequently the toxin moieties can be released within the tumor cells via chemical and/or enzymatic reactions to kill the target cells. The conjugation combines the merits of both components, i.e., the high target specificity of the monoclonal antibody and the highly potent cell killing activity of the cytotoxin moieties. However, such complexities make the pharmacokinetic and metabolic studies of ADCs highly challenging. The major challenges should include characterization of absorption, distribution, metabolism and excretion, investigation of underlying mechanisms, assessment of pharmacokinetic- pharmacodynamic relationship, and analytical method development of ADC drugs. This review will discuss common pharmacokinetic issues and considerations, as well as tools and strategies that can be utilized to characterize the pharmacokinetic and metabolic properties of ADCs.
